Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. announced that its subsidiary, Sichuan Kelun Botai Biopharmaceutical Co., Ltd., received breakthrough therapy designation from the National Medical Products Administration (NMPA) for its TROP2 ADC product, sac-TMT, in combination with PD-L1 monoclonal antibody, Tagolizumab, for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without driver gene mutations [2][3]. Group 1: Product and Clinical Development - Sac-TMT is a novel TROP2 ADC developed by Kelun Botai, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), and gynecological tumors [3][5]. - The drug utilizes a new linker and has a drug-antibody ratio (DAR) of 7.4, employing a topoisomerase I inhibitor as an effective payload to induce DNA damage in tumor cells [3][5]. - Sac-TMT has previously received four other breakthrough therapy designations for various indications, including triple-negative breast cancer (TNBC) and EGFR mutation-positive NSCLC [3][4]. Group 2: Regulatory and Market Position - Sac-TMT is the first domestically developed ADC with global intellectual property rights and the first TROP2 ADC approved for lung cancer indications globally [5]. - The drug has already been approved for two indications in China, including treatment for advanced TNBC and EGFR mutation-positive NSCLC after prior treatment [4][5]. - Kelun Botai has initiated eight registration clinical studies in China, while Merck has started 14 ongoing global Phase III clinical studies for sac-TMT in various cancer types [5]. Group 3: Collaborations and Partnerships - In May 2022, Kelun Botai granted Merck exclusive rights to develop, use, manufacture, and commercialize sac-TMT outside Greater China [4]. - Tagolizumab, the PD-L1 monoclonal antibody used in combination with sac-TMT, is the first approved PD-L1 antibody for first-line treatment of nasopharyngeal carcinoma in China [6].

Core Viewpoint - The company Kolon Biotech has received breakthrough therapy designation from the NMPA for its antibody-drug conjugate sac-TMT in combination with the PD-L1 monoclonal antibody for the treatment of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without driver gene mutations, indicating significant clinical advantages over existing treatments [1][2]. Group 1 - The breakthrough therapy designation aims to expedite the research, development, and promotion of innovative treatments to address urgent medical needs [1]. - This marks the fifth breakthrough therapy designation for sac-TMT, with previous recognitions for treating various cancers including triple-negative breast cancer (TNBC) and hormone receptor-positive breast cancer [2]. - The results of the phase 2 OptiTROP-Lung01 clinical study for sac-TMT combined with Tagoli monoclonal antibody in treating advanced or metastatic non-squamous NSCLC patients will be presented at the 2025 ASCO annual meeting [2].

Summary of IDEA Biosciences Conference Call Company Overview - **Company**: IDEA Biosciences - **Focus**: Development of innovative therapies for cancer treatment, with six clinical programs currently and a target of nine by year-end [2][1]. Key Value Drivers - **Lead Program**: Derobicertib, targeting metastatic human melanoma, currently in a registrational trial [2][1]. - **Enrollment Status**: Completed enrollment for the trial, with over 320 patients enrolled, exceeding the target of 250 [12][13]. - **Primary Endpoint**: Median progression-free survival (PFS) is crucial for potential accelerated approval, with historical PFS around 2-3 months and a target of over 5.5 months for the current study [3][8]. Clinical Data and Updates - **PFS Results**: Previous studies showed a PFS of approximately 7 months, with a specific setting achieving nearly 11 months [10][11]. - **Overall Survival (OS)**: Anticipated update on OS data from the phase two study, with historical OS in treatment-naive settings around 12-13 months [17][18]. - **Market Opportunity**: Targeting the HLA A2 negative population, with an estimated annual incidence of 4,000 to 5,000 patients in the US and Europe [20][19]. Commercial Strategy - **Commercial Organization**: Building a commercial team with key hires, including a Chief Commercial Officer and heads of various departments [24][25]. - **Regulatory Strategy**: Fast track designation from the FDA for expedited review, with ongoing discussions regarding NDA submission [14][16]. Pipeline and Future Developments - **Additional Programs**: Focus on MTAP deletion space and DLL3, with several data catalysts expected [5][6][51]. - **Combination Therapies**: Emphasis on rational combinations, particularly with PRMT5 inhibitors in lung cancer [70][71]. - **IND Filings**: Targeting multiple INDs, with a goal of one IND per year, and a record of four INDs planned for the current year [86][87]. Financial Position - **Cash Reserves**: Reported over $1 billion in cash, providing a strong financial position for ongoing and future clinical activities [88][87]. Conclusion - IDEA Biosciences is positioned for significant growth with multiple clinical programs, a robust commercial strategy, and a strong financial foundation, aiming to address unmet needs in cancer treatment through innovative therapies and strategic partnerships.

（於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：01530） 自願公告 抗VEGF/PD-1雙特異性抗體藥物707注射液 獲國家藥品監督管理局突破性療法認定 本公告由三生制药（「本公司」，連 同 其 附 屬 公 司，統 稱（「三生制药」））自 願 刊 發。 三生制药自主研發的抗VEGF/PD-1雙特異性抗體（研 發 代 碼：707注 射 液）於2025年4 月17日 獲 國 家 藥 品 監 督 管 理 局 納 入 突 破 性 治 療 品 種，適 應 症 為 一 綫 治 療PD-L1表 達 陽 性 的 局 部 晚 期 或 轉 移 性 非 小 細 胞 肺 癌。 707注射液是三生制药基於CLF2專利平台自主開發的靶向VEGF/PD-1雙特異性抗 體，目 前 正 於 中 國 開 展 多 項 臨 床 研 究，其 中 一 綫 治 療PD-L1表達陽性的局部晚期 或轉移性非小細胞肺癌已獲國家藥監局藥品審評中心（「CDE」）批准開展III期臨床 研 究。此 外，707注 射 液 正 於 國 內 開 展 聯 合 化 療 一 綫 治 療 晚 期 非 小 細 胞 肺 癌、轉 移 性結直腸癌及晚期婦科 ...